PMID- 23302045
OWN - NLM
STAT- MEDLINE
DCOM- 20140508
LR  - 20210103
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 54
IP  - 10
DP  - 2013 Oct
TI  - Whole blood transcriptional profiling reveals significant down-regulation of 
      human leukocyte antigen class I and II genes in essential thrombocythemia, 
      polycythemia vera and myelofibrosis.
PG  - 2269-73
LID - 10.3109/10428194.2013.764417 [doi]
AB  - Gene expression profiling studies in the Philadelphia-negative chronic 
      myeloproliferative neoplasms have revealed significant deregulation of several 
      immune and inflammation genes that might be of importance for clonal evolution 
      due to defective tumor immune surveillance. Other mechanisms might be 
      down-regulation of major histocompatibility (MHC) class I and II genes, which are 
      used by tumor cells to escape antitumor T-cell-mediated immune responses. We have 
      performed whole blood transcriptional profiling of genes encoding human leukocyte 
      antigen (HLA) class I and II molecules, beta2-microglobulin and members of the 
      antigen processing machinery of HLA class I molecules (LMP2, LMP7, TAP1, TAP2 and 
      tapasin). The findings of significant down-regulation of several of these genes 
      may possibly be of major importance for defective tumor immune surveillance. 
      Since up-regulation of HLA genes is recorded during treatment with epigenome 
      modulating agents (DNA-hypomethylators and DNA-hyperacetylators [histone 
      deacetylase inhibitors]) and interferon-alpha2, our findings call for prospective 
      transcriptional studies of HLA genes during treatment with these agents.
FAU - Skov, Vibe
AU  - Skov V
AD  - Department of Clinical Genetics.
FAU - Riley, Caroline Hasselbalch
AU  - Riley CH
FAU - Thomassen, Mads
AU  - Thomassen M
FAU - Larsen, Thomas Stauffer
AU  - Larsen TS
FAU - Jensen, Morten K
AU  - Jensen MK
FAU - Bjerrum, Ole Weis
AU  - Bjerrum OW
FAU - Kruse, Torben A
AU  - Kruse TA
FAU - Hasselbalch, Hans Carl
AU  - Hasselbalch HC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130515
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Alleles
MH  - Case-Control Studies
MH  - *Gene Expression Profiling
MH  - *Gene Expression Regulation
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Histocompatibility Antigens Class II/*genetics
MH  - Humans
MH  - Polycythemia Vera/*genetics
MH  - Primary Myelofibrosis/*genetics
MH  - Thrombocythemia, Essential/*genetics
EDAT- 2013/01/11 06:00
MHDA- 2014/05/09 06:00
CRDT- 2013/01/11 06:00
PHST- 2013/01/11 06:00 [entrez]
PHST- 2013/01/11 06:00 [pubmed]
PHST- 2014/05/09 06:00 [medline]
AID - 10.3109/10428194.2013.764417 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2013 Oct;54(10):2269-73. doi: 10.3109/10428194.2013.764417. Epub 
      2013 May 15.